Unknown PHASE2 INTERVENTIONAL 2-arm NCT02976142

The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer

Prospective Randomized Phase II Clinical Trial: the Efficacy of Surgical Treatment in Combinations With Intraperitoneal Immunotherapy and Systemic Chemotherapy in Patients With Gastric Cancer and Verified Free Cancer Cells

Sponsor: Moscow Clinical Scientific Center

Conditions Gastric Cancer, Metastatic

Interventions neoadjuvant chemoimmunotherapy

Updated 5 times since 2017 Last updated: Dec 12, 2016 Started: Dec 31, 2016 Primary completion: Nov 30, 2018 Completion: Dec 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastric Cancer, Metastatic, this trial is ongoing. The trial is conducted by Moscow Clinical Scientific Center and has accumulated 5 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Moscow Clinical Scientific Center

Data source: Moscow Clinical Scientific Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.